School of Pharmaceutical Sciences (Shenzhen), Sun Yat-Sen University, Shenzhen, PR China.
School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, PR China.
Eur J Med Chem. 2020 Aug 1;199:112376. doi: 10.1016/j.ejmech.2020.112376. Epub 2020 May 6.
Protein Tyrosine Phosphatase 1B (PTP1B), as one of the most important members in PTP superfamily, plays a vital role in conducting various cellular functions. So far, PTP1B has been reported to be involved in the development of many diseases including obesity, diabetes, cancers and cardiovascular diseases. Development of potent and specific PTP1B inhibitors and studies on the structure-activity relationship (SAR) between their chemical structures and their biological activity have drawn increasing attention as they could not only modulate the PTP1B functions inside the cells but also provide useful lead compounds for the treatment of various PTP1B-associated diseases. To this end, we herein summarized the recent developments of PTP1B inhibitors, and different kinds of high-throughput screening strategies for the identification of potential PTP1B inhibitors as well as their potential biomedical applications, and we also provided some perspectives in the concluding remarks in this work.
蛋白酪氨酸磷酸酶 1B(PTP1B)作为 PTP 超家族中最重要的成员之一,在执行各种细胞功能中起着至关重要的作用。迄今为止,已有报道称 PTP1B 参与了许多疾病的发展,包括肥胖症、糖尿病、癌症和心血管疾病。强效和特异性 PTP1B 抑制剂的开发以及它们的化学结构与其生物活性之间的构效关系(SAR)的研究引起了越来越多的关注,因为它们不仅可以调节细胞内的 PTP1B 功能,还可以为治疗各种 PTP1B 相关疾病提供有用的先导化合物。为此,我们在本文中总结了 PTP1B 抑制剂的最新研究进展,以及用于鉴定潜在 PTP1B 抑制剂的各种高通量筛选策略及其在生物医学中的潜在应用,并在结论中提供了一些观点。